This project belongs to the discovery, new mechanism, clinical translation and industrialization research of new drugs in the field of pharmacy. The specific manifestations are: discovery of new mechanisms of anti-inflammatory and immune regulation, and new potential targets: This series of studies has achieved effective attempts from basic to clinical transformation and industrialization: 1). Found that methionine synthase is the new mechanism of the protective effect of the compound SCM-198 2). The discovery of a new target for the production of endogenous hydrogen sulfide in the body--CSE 3). The discovery of SMYD3 as a new target for vascular aging. The discovery and drug development are based on the above new theories. We achieved: 1). First-in-class new drug SCM-198, as a lipid-lowering drug, was transferred with RMB 150 million, and has entered clinical phase II. 2). Self-designed and synthesized new H₂S targeting CSE (SPRC), as a new anti-inflammatory compound in the treatment of rheumatoid disease, completed preclinical research, transferred RMB 101 million, and began to apply for Phase I clinical trials in China and the United States. Our work has created a new mechanism of inflammation and immunity, and translated to drug candidates in clinical trials.

Fig 1 new mechanisms of first-in-class leonurine from Phase I clinical trials

Fig 2 Discovery of rheumatoid migratory neuronal navigation protein 2 (NAV2)